{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:01:54Z","timestamp":1768280514044,"version":"3.49.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"15-16","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progr\u00e8s en Urologie"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.purol.2023.09.016","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T09:24:35Z","timestamp":1696497875000},"page":"956-965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["D\u00e9tection pr\u00e9coce du cancer de la prostate\u00a0: vers un nouveau paradigme\u00a0?"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"A.","family":"Peyrottes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-5318","authenticated-orcid":false,"given":"G.","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Barret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cr\u00e9hange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-9366","authenticated-orcid":false,"given":"M.","family":"Gauth\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0512-3459","authenticated-orcid":false,"given":"A.","family":"Ruffion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-B.","family":"Beauval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De La Taille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"G.","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.purol.2023.09.016_bib0305","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.purol.2022.07.148","article-title":"French AFU Cancer Committee Guidelines \u2014 Update 2022\u20132024: prostate cancer \u2014 Diagnosis and management of localised disease","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"13","key":"10.1016\/j.purol.2023.09.016_bib0310","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schr\u00f6der","year":"2009","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.purol.2023.09.016_bib0315","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","article-title":"Mortality results from a randomized prostate-cancer screening trial","volume":"360","author":"Andriole","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.purol.2023.09.016_bib0320","article-title":"Screening for prostate cancer","volume":"2013","author":"Ilic","year":"2013","journal-title":"Cochrane Database Syst Rev [Internet]"},{"issue":"11","key":"10.1016\/j.purol.2023.09.016_bib0325","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1001\/jama.2014.2085","article-title":"Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence","volume":"311","author":"Hayes","year":"2014","journal-title":"JAMA"},{"issue":"9959","key":"10.1016\/j.purol.2023.09.016_bib0330","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13\u00a0years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2023.09.016_bib0335","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.purol.2023.09.016_bib0340","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.purol.2023.09.016_bib0345","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Heijnsdijk","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.purol.2023.09.016_bib0350","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M16-2586","article-title":"Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials","volume":"167","author":"Tsodikov","year":"2017","journal-title":"Ann Intern Med"},{"issue":"9959","key":"10.1016\/j.purol.2023.09.016_bib0355","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","article-title":"Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13\u00a0years of follow-up","volume":"384","author":"Schr\u00f6der","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2023.09.016_bib0360","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European randomized study of screening for prostate cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.purol.2023.09.016_bib0365","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMms1914228","article-title":"Reconsidering prostate cancer mortality \u2014 The future of PSA screening","volume":"382","author":"Welch","year":"2020","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.purol.2023.09.016_bib0370","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMsb2000250","article-title":"Reconsidering the trade-offs of prostate cancer screening","volume":"382","author":"Shoag","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.purol.2023.09.016_bib0375","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cncr.30474","article-title":"Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15\u00a0years","volume":"123","author":"Pinsky","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.purol.2023.09.016_bib0380","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020\u00a0update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.purol.2023.09.016_bib0385","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.purol.2023.09.016_bib0390","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouvi\u00e8re","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.purol.2023.09.016_bib0395","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"2019","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev [Internet]"},{"issue":"10","key":"10.1016\/j.purol.2023.09.016_bib0400","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.purol.2023.09.016_bib0405","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.purol.2023.09.016_bib0410","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0415","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.purol.2023.09.016_bib0420","doi-asserted-by":"crossref","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005\u00a0International Society of Urological Pathology (ISUP) consensus conference on Gleason Grading of Prostatic Carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.purol.2023.09.016_bib0425","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.22.01621","article-title":"Redefining Gleason 6 prostate cancer nomenclature: the surgeon's perspective","volume":"41","author":"Baboudjian","year":"2023","journal-title":"JCO"},{"issue":"27","key":"10.1016\/j.purol.2023.09.016_bib0430","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.22.00123","article-title":"Low-grade prostate cancer: time to stop calling it cancer","volume":"40","author":"Eggener","year":"2022","journal-title":"JCO"},{"issue":"27","key":"10.1016\/j.purol.2023.09.016_bib0435","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1200\/JCO.22.00926","article-title":"Renaming Gleason Score 6\u00a0prostate to noncancer: a flawed idea scientifically and for patient care","volume":"40","author":"Epstein","year":"2022","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0440","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0445","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.euf.2017.02.017","article-title":"Prognostic biomarkers used for localised prostate cancer management: a systematic review","volume":"4","author":"Lamy","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"17","key":"10.1016\/j.purol.2023.09.016_bib0450","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.3390\/cancers13174251","article-title":"Biomarker in active surveillance for prostate cancer: a systematic review","volume":"13","author":"Manceau","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0455","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euo.2020.08.014","article-title":"Combined use of prostate-specific antigen density and magnetic resonance imaging for prostate biopsy decision planning: a retrospective multi-institutional study using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)","volume":"4","author":"Falagario","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"15","key":"10.1016\/j.purol.2023.09.016_bib0460","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.purol.2023.09.016_bib0465","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.eururo.2012.06.053","article-title":"Evolution of the landscape of surgical management of prostate cancer in France: the case of radical prostatectomy","volume":"62","author":"Cornu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2023.09.016_bib0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.09.007","article-title":"A 5-year contemporary nationwide evolution of the radical prostatectomy landscape","volume":"34","author":"Ploussard","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.purol.2023.09.016_bib0475","series-title":"National Prostate Cancer Audit - Annual Report","year":"2020"},{"issue":"2","key":"10.1016\/j.purol.2023.09.016_bib0480","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.euf.2017.07.003","article-title":"Trends in radical prostatectomy risk group distribution in a European multicenter analysis of 28,572\u00a0patients: towards tailored treatment","volume":"5","author":"van den Bergh","year":"2019","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0485","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging\u2013based active surveillance for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol [Internet]"},{"issue":"17","key":"10.1016\/j.purol.2023.09.016_bib0490","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0495","article-title":"Patient-reported outcomes 12\u00a0years after localized prostate cancer treatment","volume":"2","author":"Donovan","year":"2023","journal-title":"NEJM Evid [Internet]"},{"key":"10.1016\/j.purol.2023.09.016_bib0500","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2021.11.006","volume":"35","author":"Olivier","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0505","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year postbiopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0510","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.juro.2016.02.2963","article-title":"How active is active surveillance? Intensity of follow-up during active surveillance for prostate cancer in the United States","volume":"196","author":"Loeb","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0515","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.juro.2013.08.088","article-title":"The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance","volume":"191","author":"Ehdaie","year":"2014","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0520","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.juro.2018.06.033","article-title":"Patient reported outcome measures for transperineal template prostate mapping biopsies in the PICTURE study","volume":"200","author":"Miah","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.purol.2023.09.016_bib0525","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate Magnetic Resonance Imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0530","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1007\/s00330-020-07256-z","article-title":"Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort","volume":"31","author":"Giganti","year":"2021","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.purol.2023.09.016_bib0535","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00345-021-03878-0","article-title":"Annual nationwide analysis of costs and post-operative outcomes after radical prostatectomy according to the surgical approach (open, laparoscopic, and robotic)","volume":"40","author":"Ploussard","year":"2022","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0540","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2021.01.030","article-title":"Robotic-assisted Versus Laparoscopic Surgery: outcomes from the first multicentre, randomised, patient-blinded controlled trial in radical prostatectomy (LAP-01)","volume":"79","author":"Stolzenburg","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.purol.2023.09.016_bib0545","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.radonc.2019.10.017","article-title":"A randomised assessment of image guided radiotherapy within a phase 3\u00a0trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer","volume":"142","author":"Murray","year":"2020","journal-title":"Radiother Oncol"},{"issue":"10","key":"10.1016\/j.purol.2023.09.016_bib0550","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10196","key":"10.1016\/j.purol.2023.09.016_bib0555","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3\u00a0trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.purol.2023.09.016_bib0560","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s12885-021-08281-x","article-title":"Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase III randomized trial","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.purol.2023.09.016_bib0565","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(16)30661-1","article-title":"Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001\u00a0PCM301): an open-label, phase 3, randomised controlled trial","volume":"18","author":"Azzouzi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.purol.2023.09.016_bib0570","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.purol.2023.09.016_bib0575","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.euf.2021.09.009","article-title":"Detailing sexual outcomes after focal therapy for localised prostate cancer: a systematic review and meta-analysis","volume":"8","author":"Fiard","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0580","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2\u00a0mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.purol.2023.09.016_bib0585","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1\u00a0and BRCA2\u00a0mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.purol.2023.09.016_bib0590","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology Position and Recommendations for 2021","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.purol.2023.09.016_bib0595","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.euf.2016.11.016","article-title":"Balancing overdiagnosis and early detection of prostate cancer using the Stockholm-3\u00a0model","volume":"4","author":"Nordstr\u00f6m","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"9","key":"10.1016\/j.purol.2023.09.016_bib0300","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Progr\u00e8s en Urologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708723002191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1166708723002191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T06:37:33Z","timestamp":1761115053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1166708723002191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":60,"journal-issue":{"issue":"15-16","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1166708723002191"],"URL":"https:\/\/doi.org\/10.1016\/j.purol.2023.09.016","relation":{},"ISSN":["1166-7087"],"issn-type":[{"value":"1166-7087","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9tection pr\u00e9coce du cancer de la prostate\u00a0: vers un nouveau paradigme\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Progr\u00e8s en Urologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.purol.2023.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}